文献速递类风湿关节炎

生物制剂改善病情抗风湿药引入后类风湿关节炎患者髋膝关节置换发生率:基于丹麦全国医疗登记的分段中断时间序列分析

Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers.
PubMed 文献 · Ann Rheum Dis · 2017-12-15

基于丹麦全国登记数据,纳入1996至2011年新发类风湿关节炎患者30404例及按年龄、性别和市镇匹配的普通人群对照297916例,采用分段线性回归中断时间序列分析比较生物制剂改善病情抗风湿药(bDMARDs)前(1996-2001)与bDMARD时代(2003-2016)髋、膝关节置换的标准化5年发生率。1996年类风湿关节炎患者髋关节置换和膝关节置换发生率分别为8.72和5.87每1000人年,普通人群对照分别为2.89和0.42。类风湿关节炎患者髋关节置换发生率自1996至2016年下降,膝关节置换发生率1996至2001年上升、2003年起下降;普通人群对照两者均上升。

要点

  • 1996年类风湿关节炎患者髋关节置换和膝关节置换发生率分别为普通人群对照的约3倍和14倍。
  • 类风湿关节炎患者髋关节置换发生率在bDMARD引入前即已开始下降。
  • 类风湿关节炎患者膝关节置换发生率在bDMARD引入后下降,而普通人群对照上升。

核心结论

  • 1996年类风湿关节炎患者髋关节置换和膝关节置换发生率分别约为普通人群对照的3倍和14倍。
  • 在类风湿关节炎患者中,bDMARDs的引入与膝关节置换发生率下降相关,而髋关节置换发生率在bDMARD引入前即已开始下降。

研究设计与样本

  • 基于丹麦全国登记数据的队列研究和中断时间序列分析。
  • 在丹麦国家患者登记中识别1996至2011年新发类风湿关节炎患者30404例,并按年龄、性别和市镇与最多10名普通人群对照匹配,共297916例对照。
  • 计算类风湿关节炎患者和普通人群对照每6个月期间的髋关节置换和膝关节置换标准化5年发生率(每1000人年)。
  • 采用分段线性回归比较bDMARD前(1996-2001)与bDMARD时代(2003-2016),中间设1年滞后干预期(2002)。

主要发现

  • 1996年类风湿关节炎患者髋关节置换和膝关节置换发生率分别为8.72和5.87每1000人年,普通人群对照分别为2.89和0.42每1000人年。
  • 1996至2016年,类风湿关节炎患者髋关节置换发生率下降,而普通人群对照上升。
  • 类风湿关节炎患者膝关节置换发生率1996至2001年上升,2003年起下降并贯穿整个bDMARD时代。
  • 普通人群对照膝关节置换发生率1996至2016年上升。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the impact of the introduction of biological disease-modifying anti-rheumatic drugs (bDMARDs) and associated rheumatoid arthritis (RA) management guidelines on the incidence of total hip (THR) and knee replacements (TKR) in Denmark. METHODS: Nationwide register-based cohort and interrupted time-series analysis. Patients with incident RA between 1996 and 2011 were identified in the Danish National Patient Register. Patients with RA were matched on age, sex and municipality with up to 10 general population comparators (GPCs). Standardised 5-year incidence rates of THR and TKR per 1000 person-years were calculated for patients with RA and GPCs in 6-month periods. Levels and trends in the pre-bDMARD (1996-2001) were compared with the bDMARD era (2003-2016) using segmented linear regression interrupted by a 1-year lag period (2002). RESULTS: We identified 30 404 patients with incident RA and 297 916 GPCs. In 1996, the incidence rate of THR and TKR was 8.72 and 5.87, respectively, among patients with RA, and 2.89 and 0.42 in GPCs. From 1996 to 2016, the incidence rate of THR decreased among patients with RA, but increased among GPCs. Among patients with RA, the incidence rate of TKR increased from 1996 to 2001, but started to decrease from 2003 and throughout the bDMARD era. The incidence of TKR increased among GPCs from 1996 to 2016. CONCLUSION: We report that the incidence rate of THR and TKR was 3-fold and 14-fold higher, respectively among patients with RA compared with GPCs in 1996. In patients with RA, introduction of bDMARDs was associated with a decreasing incidence rate of TKR, whereas the incidence of THR had started to decrease before bDMARD introduction.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Cordtz RL, Hawley S, Prieto-Alhambra D, et al. Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers. Ann Rheum Dis. 2017. PMID: 29247125. doi:10.1136/annrheumdis-2017-212424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。